The former Sarepta executive vice president and chief customer officer joins Vor Bio to advance product commercialization.

Vor Bio announced Dallan Murray as its active chief commercial officer. Murray previously served as executive vice president and then chief commercial officer at Sarepta for 12 years. Murray brings experience leading in commercial strategies, global product launches, and experience with consumer facing companies.

Jean-Paul Kress, M.D., chief executive officer and chairman of the board, touched on Murray’s appointment, saying, “We’re thrilled to welcome Dallan to Vor Bio at this important inflection point. His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy.”³

Murray aims to build upon his expansive portfolio overseeing upwards of a dozen product launches, including the first RNA therapy treatment and the first gene therapy for Duchenne muscular dystrophy. Murray’s success in product commercialization at Vertex Pharmaceutics allocated its Incivek treatment to achieve $1 billion in revenue, establishing it as the quickest product launch to reach $1 billion in biotech history.

Sarepta drama

Murray aided Sarepta in generating an estimated $1.8 billion in net product revenue in 2024, establishing Sarepta as one of the most profitable organizations in biotech. Despite the successful year, 2025 would bring turmoil to the company, with FDA requesting a halt on Elevidys shipments following the deaths of three separate patients using the therapy. Sarepta (with Murray serving as executive vice president) initially refused to cease shipments with the organization, saying at the time, “Based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population, we will continue to ship Elevidys to the ambulant population.”²

Shortly following its response to the FDA, Saretpa quickly adjusted course and adhered to the request, stopping all shipments of Elevidys to patients. The decision proceeded reports of a third death due to Elevidys paired with pressure from FDA to cease shipments.Results yielded immense market implications, as Saretpa’s stock plummeted 36% in a single day, while receiving multiple downvotes from market analysts. The fallout from the back and forth forced Saretpa to part ways with roughly 500 employees, including Murray, with the decision aiming to save the company $400 million annually.

Following the loss of roughly 36% of Saretpa’s workforce Saretpa was able to resume shipments after the halt was lifted from FDA. This subsequentially provided a boost to Saretpa stock following its fall just weeks prior.

Looking ahead

With his time at Saretpa in the rearview, Murray is joining Vor Bio with expectations set on advancing the organization’s pipeline employing strategic commercialization and marketing efforts.

“Vor Bio is building a company with great potential,” said Mr. Murray. “With telitacicept already approved in China for multiple autoimmune indications and now advancing through global Phase 3 development, I look forward to the opportunity to bring a much-needed treatment to patients around the world. I’m excited to join the team and help lay the commercial and strategic foundation for long-term success.”³

Sources

1. IGNYTE Trial Investigators Press FDA to Reconsider Replimune CRL Amid Promising Melanoma Data, Leadership Shakeup Pharmaceutical Executive July 30, 2025 https://www.pharmexec.com/view/ignyte-trial-fda-replimune-crl-melanoma-
2. Recapping the Sarepta Saga—And Implications for Industry Pharmaceutical Executive July 23, 2025 https://www.pharmexec.com/view/recapping-the-sarepta-saga-and-implications-for-industry
3. Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer Vor Biopahrma https://finance.yahoo.com/news/vor-bio-appoints-seasoned-biotech-123000361.html